Pharmacokinetics and dose recommendations for cyclosporine and tacrolimus when coadministered with ABT-450, ombitasvir, and dasabuvir

American Journal of Transplantation

Volumn 15, Issue 5, 2015, Pages 1313-1322

  Badri, P ^a   Dutta, S ^a   Coakley, E ^a   Cohen, D ^a   Ding, B ^a   Podsadecki, T ^a   Bernstein, B ^a   Awni, W ^a   Menon, R ^a  

^a ABBVIE INC   (United States)

Author keywords

calcineurin inhibitor: cyclosporine A (CsA); calcineurin inhibitor: tacrolimus; clinical research practice; immunosuppressant; infection and infectious agents; infectious disease; liver transplantation hepatology; pharmacokinetics pharmacodynamics; pharmacology; viral: hepatitis C

Indexed keywords

CYCLOSPORIN A; DASABUVIR; OMBITASVIR; PARITAPREVIR; RITONAVIR; TACROLIMUS; ABT-267; ABT-333; ABT-450; ANILIDE; ANTIVIRUS AGENT; CARBAMIC ACID DERIVATIVE; CYCLOSPORIN; MACROCYCLIC COMPOUND; SULFONAMIDE; URACIL;

ABNORMAL LABORATORY RESULT; ADULT; AREA UNDER THE CURVE; ARTICLE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; ELIMINATION HALF-LIFE; ELIMINATION RATE CONSTANT; FAINTNESS; FEMALE; GRAFT RECIPIENT; HUMAN; HUMAN EXPERIMENT; LIMIT OF QUANTITATION; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM PLASMA CONCENTRATION; MULTIPLE DRUG DOSE; NAUSEA; NORMAL HUMAN; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; SINGLE DRUG DOSE; STEADY STATE; VOMITING; ADOLESCENT; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG EFFECTS; HEPACIVIRUS; HEPATITIS C; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; ANILIDES; ANTIVIRAL AGENTS; AREA UNDER CURVE; CARBAMATES; CYCLOSPORINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEALTHY VOLUNTEERS; HEPACIVIRUS; HEPATITIS C; HUMANS; MACROCYCLIC COMPOUNDS; MALE; MIDDLE AGED; SULFONAMIDES; TACROLIMUS; URACIL; YOUNG ADULT;

EID: 84928068548     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.13111     Document Type: Article

References (28)

1. World Health Organization (WHO). Hepatitis C Wkly Epidemiol Rec. 2011; 86: 445-447.
2. Pawlotsky JM.; Pathophysiology of hepatitis C virus infection and related liver disease. Trends Microbiol. 2004; 12: 96-102.
3. Terrault NA.; Treatment of recurrent hepatitis C in liver transplant recipients. Clin Gastroenterol Hepatol. 2005; 3: S125-131.
4. Berenguer M.; Natural history of recurrent hepatitis C. Liver Transpl. 2002; 8: S14-18.
5. Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014; 370: 1594-1603.
6. Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014; 370: 1973-1982.
7. Mantry P, Kwo P, Coakley E, et al. M12-999: ABT-450/r/ABT-267 + ABT-333 + ribavirin in liver transplant recipients with recurrent HCV genotype 1 infection [abstract 1325]. Am J Transplant. 2014; 14: 3.
8. Neoral® (cyclosporine) [US package insert]. East Hanover, NJ; Novartis, May 2013. Available at: https://www.pharma.us.novartis.com/product/pi/pdf/neoral.pdf. Accessed September 9, 2014.
9. Prograf® (tacrolimus) [US package insert]. Northbrook, IL; Astellas Pharma US, Inc.; September 2013. Available at: http://www.astellas.us/docs/prograf.pdf. Accessed September 9, 2014.
10. Krishna R, Bergman A, Larson P, et al. Effect of a single cyclosporine dose on the single-dose pharmacokinetics of sitagliptin (MK-0431), a dipeptidyl peptidase-4 inhibitor, in healthy male subjects. J Clin Pharmacol. 2007; 47: 165-174.
11. Kalliokoski A, Niemi M.; Impact of OATP transporters on pharmacokinetics. Br J Pharmacol. 2009; 158: 693-705.
12. Norvir® (ritonavir) [US package insert]. North Chicago, IL; AbbVie Inc.; November 2013. Available at: http://www.rxabbvie.com/pdf/norvirtab-pi.pdf. Accessed September 09, 2014.
13. Zhang L, Strong JM, Qiu W, Lesko LJ, Huang S-M.; Scientific perspectives on drug transporters and their role in drug interactions. Mol. Pharm. 2006; 3: 62-66.
14. Bow DAJ, Liu J, Kavetskaia O, et al. A mechanistic non-clinical assessment of drug-drug interactions (metabolism and transporters) with the hepatitis C virus (HCV) regimen: ABT-450/r, ombitasvir and dasabuvir. Poster presented at: 2014 American Association for the Study of Liver Diseases/European Association for the Study of the Liver Special Conference on Hepatitis C; 2014; Sept. 12-13; New York, NY.
15. Berenguer M.; Management of hepatitis C virus in the transplant patient. Clin Liver Dis. 2007; 11: 355-376.
16. Campana C, Regazzi MB, Buggia I, Molinaro M.; Clinically significant drug interactions with cyclosporin. An update. Clin Pharmacokinet. 1996; 30: 141-179.
17. Amundsen R, Åsberg A, Ohm IK, Christensen H.; Cyclosporine A- and tacrolimus-mediated inhibition of CYP3A4 and CYP3A5 in vitro. Drug Metab Dispos. 2012; 40: 655-661.
18. Nara M, Takahashi N, Miura M, et al. Effect of itraconazole on the concentrations of tacrolimus and cyclosporine in the blood of patients receiving allogeneic hematopoietic stem cell transplants. Eur J Clin Pharmacol. 2013; 69: 1321-1329.
19. Bernstein B, Menon R, Klein CE, et al. Pharmacokinetics, safety and tolerability of the HCV protease inhibitor ABT-450 with ritonavir following multiple ascending doses in healthy adult volunteers [abstract 58]. Global Antiviral J. 2009; 5; 53. Available at: http://www.informedhorizons.com/hepdart2009/pdf/AbstractBook-HEPDART09-sent.pdf. Accessed September 17, 2014.
20. Vogel M, Voigt E, Michaelis HC, et al. Management of drug-to-drug interactions between cyclosporine A and the protease-inhibitor lopinavir/ritonavir in liver-transplanted HIV-infected patients. Liver Transpl. 2004; 10: 939-944.
21. Christians U, Jacobsen W, Benet LZ, Lampen A.; Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clin Pharmacokinet. 2002; 41: 813-851.
22. Jain AB, Venkataramanan R, Eghtesad B, et al. Effect of coadministered lopinavir and ritonavir (Kaletra) on tacrolimus blood concentration in liver transplantation patients. Liver Transpl. 2003; 9: 954-960.
23. Undre NA.; Pharmacokinetics of tacrolimus-based combination therapies. Nephrol Dial Transplant. 2003; 18: i12-15.
24. Coilly A, Roche B, Dumortier J, et al. Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience. J Hepatol. 2014; 60: 78-86.
25. Kwo PY, Ghabril M, Lacerda MA, Joseph Tector A, Fridell JA, Vianna R.; Telaprevir with peginterferon/ribavirin for retreatment of null responders with advanced fibrosis post-orthotopic liver transplant. Clin Transplant. 2014; 28: 722-727.
26. Kowdley KV, Lawitz E, Poordad F, et al. Safety and efficacy of interferon-free regimens of ABT-450/r, ABT-267, ABT-333 +/- ribavirin in patients with chronic HCV GT1 infection: results from the AVIATOR study [abstract 3]. J Hepatol. 2013; 58: S2.
27. Poordad F, Lawitz E, Kowdley KV, et al. Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med. 2013; 368: 45-53.
28. Farnik H, Zimmermann T, Herrmann E, et al. Telaprevir drug monitoring during antiviral therapy of hepatitis C graft infection after liver transplantation. Liver Int. 2014; Mar 20. doi: 10.1111/liv.12532. [Epub ahead of print].